This year’s World Health Assembly (WHA), which has just concluded in Geneva, Switzerland, was historic, according to consumer group Health Action International (HAI), which says it followed some of the most controversial issues that were up for discussion on this ambitious agenda: the debates and action around agenda items 11.3 Global Strategy and Plan of Action (GSPA) on Public Health Innovation and Intellectual Property, and 11.20 Counterfeit Medical Products.
On both issues, the debate played out more or less with opposing positions taken by Northern and Southern countries, it stated (See also separate views on the meeting from the IFPMA).
11.3 Global Strategy and Plan of Action (GSPA) on Public Health Innovation and
Intellectual Property
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze